Growth Hormone and Endocrine Research Track
The compounds people research for GH signaling and body composition.
Endocrine peptides deserve more caution than hype. This track separates approved clinical use, emerging evidence, and experimental research.
Who this is for
GH signaling, body composition, recovery, muscle preservation, visceral fat, hormonal pathways, age-related endocrine decline.
How this track is graded
These compounds act on hormone signaling, which raises the stakes on evidence, oversight, and regulatory status. This track sorts approved clinical use from emerging and experimental research.
Snapshot
| Compound | Tier | What people research it for | What the evidence shows |
|---|---|---|---|
| Tesamorelin | A | Visceral fat reduction. | FDA-approved GHRH analog with human trials. |
| Sermorelin | B | GH release research. | Limited human data. |
| Ipamorelin | B | Selective GH secretagogue research. | Mostly preclinical. |
| CJC-1295 | B | GHRH analog research. | Limited human data. |
| CJC-1295 No DAC / Ipamorelin | B | Pulse-oriented GH research. | Preclinical. Blend. |
| GHRP-6 | B | Ghrelin-receptor GH research. | Preclinical. |
| IGF-1 LR3 | B | IGF pathway research. | Preclinical. |
Pressure Test · Lead compound
Tesamorelin
Mechanism
GHRH analog.
Evidence
Tier A. Human trials.
Risk
Medical supervision. IGF-1 elevation.
Standing
FDA approved for HIV lipodystrophy.
Comparisons
Coming
- Ipamorelin vs GHRP-6
- CJC-1295 vs Sermorelin
Download the Peptide Research Playbook
Stop guessing. Learn how to evaluate peptide claims before you trust them.
Free Peptide Research Playbook on signup. No spam. Unsubscribe anytime.